Sequana Medical NV
XBRU:SEQUA

Watchlist Manager
Sequana Medical NV Logo
Sequana Medical NV
XBRU:SEQUA
Watchlist
Price: 0.85 EUR -1.16% Market Closed
Market Cap: 34.4m EUR
Have any thoughts about
Sequana Medical NV?
Write Note
SEQUA
/
Income Statement
/
Gross Profit

Sequana Medical NV
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sequana Medical NV
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Sequana Medical NV
XBRU:SEQUA
Gross Profit
-€3.6m
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nyxoah SA
XBRU:NYXH
Gross Profit
€2.7m
CAGR 3-Years
310%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biocartis Group NV
XBRU:BCART
Gross Profit
€31.2m
CAGR 3-Years
27%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Ion Beam Applications SA
XBRU:IBAB
Gross Profit
€134.4m
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Sequana Medical NV
Glance View

Market Cap
34.4m EUR
Industry
Health Care

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

SEQUA Intrinsic Value
1.69 EUR
Undervaluation 50%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Sequana Medical NV's Gross Profit?
Gross Profit
-3.6m EUR

Based on the financial report for Jun 30, 2024, Sequana Medical NV's Gross Profit amounts to -3.6m EUR.

What is Sequana Medical NV's Gross Profit growth rate?
Gross Profit CAGR 3Y
-31%

Over the last year, the Gross Profit growth was -7%. The average annual Gross Profit growth rates for Sequana Medical NV have been -31% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.